Janssen Pharmaceutical Cos.'s average net price increase for 2017 reflects the demands of payers and providers for greater discounts and rebates. The company reported that while its average list price (wholesale acquisition cost) increased 8.1% – pretty much the same as the previous year – the average net price (wholesale acquisition cost minus rebates, discount and returns) declined 4.6%.
Janssen disclosed the pricing information in its second annual US Transparency Report, released March 9, which also includes information on the company's R&D investments, sales and marketing expenditures and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?